Background

Scientists have learned that a build-up of amyloid plaque in the brain is neurotoxic (which means it is bad for brain cells) and can cause brain cells to degenerate and die leading a loss of brain cells and subsequent memory loss/dementia. We are conducting several studies to see if a study medication can remove the amyloid plaque that is currently present in the brain and also whether removing this plaque can either stop or slows the loss of memory.

Criteria to participate

Some of the criteria patients must satisfy to participate are:

  • Be between 50 and 85 years old
  • Have a study partner (i.e. someone who is with you 8 hours or more each week and would be willing to come to the center about twice year with you)
  • Demonstrate a mild level of memory loss when tested
  • Have a positive PET (brain scan) for amyloid plaque
  • Can have an MRI (that is no metal in your head or upper torso)
  • Has no medical conditions which may also cause memory loss (e.g. Parkinson’s, uncontrolled sleep apnea, and stroke history)

About the Study

Once the study criteria are met, the patient will receive either the study medication or a placebo for the duration of the study; neither the patient nor the doctor will know which is assigned. The study medication is a large protein which means it cannot be made into a pill but must be dissolved in saline and injected into a vein in your arm. The medication is administered once a month over about 1½ hours. During the study, repeat MRI scans of the brain are made and once each year, a amyloid PET scan is conducted. The study will last 18 to 24 months. Once the study is completed, the patient is then offered real medication (no placebo) for 2 years or until the medication is available on the market. There is no cost to the patient for medical care provided in the study nor for any of the scans, memory testing, or medication.

Current Studies

We are currently conducting the following studies with medications which seek to remove brain amyloid plaque

Study

Sponsor

Study medication

NCT number

Study Status

CREAD1

Roche

Crenezumab

NCT02670083

Closed to new patients

CREAD2

Roche

Crenezumab

NCT03114657

Enrollment open

Engage

Biogen

Aducanumab

NCT02477800

Enrollment open

You may use the NCT number to learn more about the study we are conducting by going to clinicaltrials.gov and entering the number in the search bar.